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surgery after chemotherapy for initially 
unresectable stage iii non-small cell lung 
cancer
By the european lung Cancer Working party
A B S T R A C T
BACKGROUND stage iii non-small cell lung cancer represents a heterogeneous group 
of diseases for which multimodal therapy is today recommended including surgery, 
radiotherapy and chemotherapy. 
PATIENTS AND METHODS the purpose of the study was to retrospectively identify 
factors predictive of secondary complete resection, in a series of patients with initially 
unresectacle, non metastatic non small Cell lung Cancer (nsClC) who were treat-
ed with pre-operative chemotherapy. patients were randomised between 3 courses 
of mip (mitomycin C 6mg/m2; ifosfamide 3g/m2; cisplatin 50mg/m2) or supermip 
(mitomycin C 6mg/m2; ifosfamide 4.5g/m2; cisplatin 60mg/m2, carboplatine 200mg/
m2). if, after 3 courses of chemotherapy, the tumour became resectable, surgery was 
performed followed by mediastinal irradiation.
RESULTS there were 351 ellgible patient: 176 in the mip arm, 175 in the supermip 
arm; 43% and 51% with stages ii A and ii B, respectively. After chemotherapy, sur-
gery was performed in 54 (15%, 95% Ci: 12%-20%) patients. Complete resection (r0) 
was obtained in 40 patients. two independent predicting factors of complete resection 
were identified: n status (or: 0.06 in disfavour of n3; 95% Ci: 0.007-0.410; p=0.005) 
and objective response to chemotherapy (or: 3.90 in favour of objective response; 
95% Ci: 1.90-7.98; p <0.001).
CONCLUSIONS in initially unresectable stage iii nsClC, the absence of n3 nodal in-
volvement or a response to chemotherapy is associated with a higher chance to achieve 
a complete resection.
I N T R O D U C T I O N
stage iii non-small cell lung cancer (nsClC) is a heterogeneous group of diseases 
for which multimodal therapy is today recommended, including surgery, radiotherapy 
and chemotherapy. practically, various approaches are possible [1-3]: induction therapy 
followed by surgery in initially resectable tumours, chemotherapy combined with chest 
irradiation in case of unresectable disease, chemotherapy alone when disease extent is 
locoregionally too extensive precluding effective local treatment. in some situations, 
induction may render the tumour resectable. surgery or radiotherapy as a single treat-
ment modality should not be considered anymore as a first-choice option.
the main problem of the current staging classification of nsClC is its operational 
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validity. Although the international staging system (iss) has a 
good prognostic value, it is not very helpful in making a thera-
peutic decision, particularly in stage iii nsClC. indeed, the 
therapeutic decision is often guided by subjective parameters 
such as the local expertise. the consideration of a tumour 
as resectable or treatable with curative radiotherapy is often 
surgeon- or radiotherapist-dependent and it is thus a matter 
of some subjectivity due to a lack of objective criteria. this 
makes difficult the interpretation of the literature.
the european lung Cancer working party (elCWp) 
has conducted, a couple of years ago, a randomised trial com-
paring two different dose-intensity induction chemotherapy 
regimens before chest irradiation in patients with initially 
non metastatic unresectable nsClC [4]. the study failed to 
demonstrate survival improvement with a high dose induc-
tion chemotherapy despite a significantly increased objective 
response rate and the achievement of a higher dose-intensity. 
After induction chemotherapy and before chest irradiation, 
the disease was assessed for secondary surgery. of 351 eligible 
patients included in the above trial, secondary surgery was 
performed in 54 [4]. in the present study, we retrospectively 
analyse factors predicting secondary complete resection in 
the above series of patients, initially considered as having 
unresectable tumour.
P A T I E N T S  A N D  M E T H O D S
inclusion and exclusion criteria in the aforementioned 
elCWp trial 01953 [4] are listed in table 1. except for bulky 
involvement (defined as a disease considered by the local 
surgeon as too massive to permit surgical resection), mediasti-
noscopy with biopsy was recommended prior to chemotherapy 
to confirm mediastinal dissemination and unresectability.
eligible patients were randomised to receive 3 courses 
of mip (mitomycin C 6 mg/m²; ifosfamide 3g/m²; cisplatin 
50 mg/m²) or 3 courses of supermip (mitomycin C 6 mg/m²; 
ifosfamide 4.5 g/m²; cisplatin 60 mg/m², carboplatine 200 mg/
m²). stratification of patients was also performed according 
to the initial tnm stage, histological subtype, Karnofsky ps 
and treating centre. Courses were repeated every 3 to 4 weeks, 
according to haematological and renal function recovery. if 
delay between 2 courses was more than 5 weeks, patient went 
off treatment.
evaluation of tumour response was performed on week 9 
(later if chemotherapy had to be delayed). if the tumour was 
rendered resectable, surgery was performed followed by medi-
astinal irradiation. for responding but non resectable, stable or 
locally progressing tumours, chest irradiation was given (60 gy 
over 6 weeks with 2 gy daily fractions to the primary tumour 
and the known area of lymph node involvement). if the patient 
developed distant metastases, went off protocol.
restaging, including all tests performed during the initial 
work-up [4] excepting mediastinoscopy, was repeated after the 
first three courses of chemotherapy and for responders and 
those with stable disease, again at the end of therapy. After 
treatment discontinuation, patients were examined with bio-
logical tests (as initially performed) and chest X-ray, every 2 
months for the first 6 months and every 3 months thereafter. 
A complete work-up was recommended every 6 months.
evaluation for response after completion of three courses 
of chemotherapy, as well as review of the initial tnm stage, 
was performed during regular meetings of the group by at 
least three independent observers. Complete response (Cr) 
was defined as disappearance of all parameters of disease. 
in cases of measurable disease, partial response (pr), was 
defined as a ≥50% greater decrease of the total tumour load 
(the tumour area calculated by the multiplication of the longest 
diameter by the greatest perpendicular diameter), without 
the appearance of new lesions or progression of any existing 
lesion. in assessable disease, pr was defined as an estimated 
decrease in tumour size of ≥50%. progressive disease (pd) 
was defined as a >25% increase in one or more measurable or 
assessable lesions or the appearance of a new lesion. All other 
circumstances were classified as no change (nC). patients with 
early death (ed) due to pd before evaluation or with toxic 
death due to chemotherapy or with early chemotherapy stop-
ping for toxicity, were considered in response evaluation and 
TABLE 1. inclusion and exclusion study criteria
Inclusion criteria
	histologically proven nsClC;
	initially unresectable non metastatic tumour without homolateral 
malignant pleural effusion;
	no prior history of malignancy except non melanoma skin cancer 
or in situ carcinoma of the cervix and “cured” malignant tumour 
(more than 5-year disease-free interval);
	no prior therapy with chemotherapy, surgery or irradiation;
	age ≤75 years;
	Karnofsky performance status (ps) ≥60;
	good renal (serum creatinine level ≤1.5 mg/dl), hepatic (serum bili-
rubin level ≤1.5 mg/dl) and haematological (WBC count ≥4,000/μl 
and platelet count ≥100,000/μl) functions;
	no recent (<3 months before the date of treatment) myocardial 
infarction and no active congestive heart failure or cardiac arrhythmia 
requiring medical treatment;
	no uncontrolled infectious disease or other serious medical or 
psychiatric illness precluding adherence to the study protocol
	Accessibility for follow-up and provision of informed consent
Exclusion criteria
	patients requiring prompt irradiation (i.e. because of spine invasion 
by tumour)
	functional or anatomical contra-indication to chest irradiation.
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were characterised as treatment failures. WHo criteria were 
used to assess toxicity and histological subtypes.
in case of surgery, at least a lobectomy was required. 
An upper or lower radical dissection of the mediastinum 
was required in case of mediastinal node dissemination. 
mediastinal nodes had to be looked for and picked up at 3 
levels including paratracheal and subcarinal sites. marginal 
tissue had to be collected at least at the level of the bronchial 
stump, the mediastinal lymph nodes and all structures in 
close contact with tumour infiltration. other sites of possible 
intrathoracic metastases had to be thoroughly searched. for 
postoperative radiotherapy, the target volume had to include 
the areas of entire regional lymphatic drainage: ipsilateral 
hilum including the bronchial stump with a 2 cm margin of 
uninvolved pulmonary tissue (as seen on the radiographs), 
entire mediastinum from the suprasternal notch (including the 
mediastinoscopy scar) to not less than 5 cm below the carina 
and across the trachea to include 1 cm of contralateral lung. 
inferior mediastinal nodes (down to the diaphragm) had to 
be irradiated in case of lower lobe tumours. the radiation 
dose was as follows: the dose to the isocenter in the central 
plane of the volume was 60 gy with lung tissue correction 
factor (0.3 or Ct-based) given as daily fraction of no more 
than 2 gy; the isodose encompassing the target volume had 
to be not less than 56 gy. Variation within the target volume 
should not exceed 10%.
According to pathological evaluation and ptnm staging, 
resected tumours were classified in 4 categories: i) complete 
response (r0) if no tumour was found in neither lung tissue, 
neither thoracic nodes; ii) complete resection (r0) if all 
the margins and all distant nodes were free of tumour; iii) 
incomplete resection if resection was performed with gross 
pathologic tissue left behind or if margins were still positive 
for tumour or if more distant nodes were still involved (r1= 
microscopical residual tumour and r2= macroscopical re-
sidual tumour); iV) unresectable if no tumour resection was 
performed at thoracotomy.
overall survival and response duration were dated from 
the day of randomisation. survival distributions were esti-
mated by the Kaplan-meier method. the log-rank test was 
used to compare survival distributions. p values (two-tailed) 
for testing the null hypothesis of the equality of proportions 
were calculated using a fisher’s exact test or a X² test. uni-
variate and multivariate analysis for prognostic factors were 
performed by adjusting the data with logistic regression models 
and choosing as dependent characteristic the surgery result, 
dichotomised as complete response/complete resection or 
incomplete resection/unresectable. Covariates with a p value 
<0.20 were retained to be tested in a multivariate model, us-
ing a backward stepwise method for the selection of variables 
to be retained in the final model. Coefficient estimates were 
obtained by the maximum likelihood method.
Among all eligible patients for the above mentioned el-
CWp 01953 protocol, only those with clinical stage iii were 
included in the present analysis. inoperable patients with stage 
i and ii were eligible for the trial 01953 but not for the present 
analysis since the inoperable status could not be affected by 
induction treatment.
the present study was approved by the local ethical com-
mittee of the participating institutions.
TABLE 2. main characteristics of the operated patients.
Characteristics MIP Super MIP
number of patients 27 27
Age median (years) 58 54
sex
male 
female 
22
5
25
2
Histology
squamous cell carcinoma
Adenocarcinoma
other non-small cell
15
7
5
12
10
5
initial Karnofsky ps
≥80
≤70
23
4
27
0
initial clinical stage
iiiA
iiiB
19
8
21
6
Clinical response to induction chemotherapy
Cr
pr
nC
stop for toxicity
1
18
7
1 *
0
18
5
4 **
ps: performance status; Cr: complete response; pr: partial response; nC: no change; *: renal failure; **: renal failure in 3 and skin allergy in 1
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R E S U L T S
Among 351 eligible patients randomised between Janu-
ary 1996 and April 2002, 340 had stage iii; out of these 340, 
surgery was performed in 54 (15.4%, 95% confidence interval 
Ci: 12% - 20%), 27 in the mip arm and 27 in the supermip. 
Characteristics of these patients according to the chemo-
therapy regimen, are shown in table 2 the two groups were 
not significantly different. the majority of patients had iiiA 
disease (74%) and were clinically documented as objective 
responders to chemotherapy (69%).
lobectomy was performed in 30 cases, pneumectomy in 
22 and exploration only in 2. five postoperative deaths were 
documented (13%): 3 in the mip arm and 2 in the supermip 
(2 right pneumectomies, 2 left pneumectomies and 2 right 
upper lobectomies).
Clinical downstaging was achieved in 29 patients (54%): 
16 in the mip arm and 13 in the supermip. t status was 
downstaged in 21 and n status in 18 cases.
Complete resection (r0) was obtained in 40 patients 
including 23 with clinical tn downstaging: 21 in the mip 
arm and 19 in the supermip; 29 in initial clinical stage iiiA 
and 11 in initial clinical stage iiiB (including one stage t2n3 
with histologically proven supraclavicular adenopathy). thus, 
the overall rate of complete resection was 11% (95% Ci: 8%-
15%). By excluding patients with stage i-ii, it was 12% (95% 
Ci: 9%-16%). there were 5 pathological complete responses 
(13%): 2 in the mip arm and 3 in the supermip one.
survival of the 40 completely resected patients (median 
follow up: 43 months; range: 6-87) was 77% at one year, 54% 
at two years and 48% at three years with a median survival 
of 30 months. there was no difference according to chemo-
therapy regimen.
A prognostic factor analysis was performed to determine 
characteristics predicting complete resection. the following 
baseline characteristics were analysed: age, sex, histology, type 
of lesions, Karnofsky ps, initial t, n and stage and a single 
treatment variable: response to induction chemotherapy. 
univariate analysis results are shown in table 3. three factors 
were found to be statistically significant predictors for r0: n, 
stage and response to induction chemotherapy. multivariate 
analysis with logistic regression identified two independent 
predicting factors: n status (or: 0.06 in disfavour of n3; 95% 
Ci: 0.007-0.410; p = 0.005) and objective response to induction 
chemotherapy (or: 3.90 in favour of objective response; 95% 
Ci: 1.90-7.98; p <0.001).
TABLE 3. predictive factors of complete resection: univariate analysis (n = 340, excluding stages i-ii patients)
Factor N pts N R0 (%) p
age (years) ≤60
>60
162
178
25 (15.4)
15 (8.4)
0.06
sex male
female
289
51
33 (11.4)
7 (13.7) 0.64
Histology squamous cell
Adenocarcinoma
other non-small cell
164
120
56
20 (12.2)
11 (9.2)
9 (16.1) 0.41
initial Karnofsky ps ≥80
≤70
299
41
38 (12.4)
3 (7.3) 0.45
type of lesion evaluable
measurable 
127
213
12 (9.4)
28 (13.1) 0.39
Weight loss <5%
≥5%
210
100
27 (12.9)
8 (8) 0.25
t 1-2
3
4
140
82
117
22 (15.7)
8 (9.8)
10 (8.5) 0.12
n 0-1
2
3
54
196
90
10 (18.5)
29 (14.8)
1 (1.1) 0.001
stage (iss 86) iiiA
iiiB
162
178
29 (17.9)
11 (6.2) 0.001
or to induction chemotherapy Yes
no 
137
203
27 (19.7)
13 (6.4) <0.001
ro: objective response; ps: performance status; iss: international staging system
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terion does not matter in the present analysis since an initial 
medical contra-indication for surgery would remain a cause 
of exclusion from surgery even after successful induction 
chemotherapy. on the contrary, disease extent can be modi-
fied by primary chemotherapy and clinical downstaging can 
be documented at the preoperative assessment, rendering the 
tumour resectable. in our series, tnm downstaging, allowing 
the surgeon to reconsider his/her decision, was observed in 
54% of the patients.
A main problem interfering with surgeon’s decision about 
resectability is the relative lack of objective criteria on which 
to base his/her decision. His/her own experience is impor-
tant. some surgeons perform extensive surgery for stage iii 
nsClC while others are more conservative. in our study, 
the decision on non-resectability was determined, before and 
after induction chemotherapy, by a multidisciplinary team 
including thoracic surgeon, chest physician, medical oncolo-
gist and radiation oncologist. some criteria that we used are 
commonly accepted such as bulky mediastinal involvement 
already present on standard chest X-ray [30].
the high mortality rate (13%) observed is essentially due 
to the poor ps of the group of patients, initially considered 
unresectable and operated on after chemotherapy. moreover, 
4 of the 6 patients underwent pneumectomy.
our analysis performed in initially unresectable nsClC 
allowed us to identify two main factors predicting resectability 
after induction chemotherapy, pre-treatment clinical n status 
and response to chemotherapy. more specifically, initial n3 
stage (although admittedly the confidence interval was large 
as there was only one n3 tumour completely resected in our 
series) or the absence of response to chemotherapy were as-
sociated with a low chance to achieve complete resection.
our data do not support the mandatory role of surgery 
in stage iii disease and this is in accordance with results re-
ported by others [31,32]. Cure can be achieved with combined 
chemoradiotherapy only [31]. recently, in a large randomised 
trial, no significant difference in survival was found, in 
pathological stage iiiA n2 nsClC when surgery was added 
to chemoradiotherapy [32]. the impact of surgery on survival, 
in other stage iii disease, remains to be demonstrated by 
controlled studies.
With the aforementioned methodological caution, our 
study shows that in initially unresectable stage iii nsClC, 
the absence of n3 lymphadenopathy or a response to chemo-
therapy is associated with a higher chance to achieve a com-
plete resection after induction chemotherapy. Whether this 
approach is preferable than chemoradiotherapy alone remains 
to be demonstrated by prospective randomised trials.
PA R T I C I PA T I N G  M E M B E R S  A N D  I N S T I T U T I O N S 
T O  T H E  S T U D y
participating institutions (investigators) of the european 
lung Cancer Working party to the present study were as fol-
D I S C U S S I O N
the important contribution of the present study is the 
information provided about the rate of secondary complete 
resections (12%) after induction chemotherapy in patients 
with nsClC initially considered unresectable together with 
the identification of factors predicting successful outcome of 
surgery in this situation.
our findings are based on a retrospective analysis of data 
obtained from a prospective randomised trial comparing two 
induction chemotherapy regimens prior to chest irradiation 
in patients with nsClC [4]. initially resectable cases were 
excluded by definition from the analysis. Among 340 eligible 
patients with stage iii, surgery was performed in 16% and 
complete resection was obtained in 12% (40 among 54 oper-
ated patients). this observation demonstrates that secondary 
surgery with a r0 outcome can be applied in only a small mi-
nority of patients. Among other published randomised studies 
[5-26] including a sequential arm with chemotherapy followed 
by irradiation and performed in unresectable nsClC, only 
three have reported the number of patients operated on after 
induction therapy: a french trial [9] reporting 5 patients from 
a total of 176 (2.8%), a Japanese study 5 patients from 320 
(1.6%) [19] and a previous trial conducted by our group [24] 
reporting 32 patients from a total of 462 (7%).
We acknowledge that our findings must be treated with 
caution due to some methodological problems: although the 
data were obtained from a prospectively randomised trial, the 
present analysis of the “surgical” results was retrospectively 
performed. the reason why it was not scheduled from the 
beginning was that on the basis of the available literature and 
of our previous study [24] we did not expect to have a 15% 
rate of successful secondary surgery with an overall 11% rate 
of complete resection. Because of the retrospective nature 
of the analysis:
1. it was practically impossible to establish the criteria on 
which the surgeon based his decision about the initial re-
sectability of the tumour or its resectability after induction 
chemotherapy in each individual patient. furthermore, 
pet scan was not available at that time.
2. some of the so called “no change” cases were in fact tu-
mours with a minor response, not strictly stable disease 
and therefore the regression of the lesions, even if it did not 
reach the threshold requested by the WHo definition for 
pr characterisation, it could have been sufficient enough 
to convince the surgeon that full resection was possible. 
in addition, some recommend surgery in those situations 
because it is known that residual masses seen on chest Ct 
scan may not contain viable tumour [27-29].
resectability of a lung tumour depends on three main 
criteria: operability of the patient, disease extent (based on 
the tumour stage) and decision of the surgeon. the first cri-
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